Weekly Research Analysts’ Ratings Updates for Smith & Nephew SNATS (SNN)

A number of firms have modified their ratings and price targets on shares of Smith & Nephew SNATS (NYSE: SNN) recently:

• 5/25/2026 – Smith & Nephew SNATS had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 5/11/2026 – Smith & Nephew SNATS was given a new $31.85 price target by Sanford C. Bernstein.
• 5/11/2026 – Smith & Nephew SNATS had its price target lowered by Canaccord Genuity Group Inc. from $32.00 to $30.00. They now have a “hold” rating on the stock.
• 5/9/2026 – Smith & Nephew SNATS was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 4/24/2026 – Smith & Nephew SNATS was given a new $32.00 price target by Canaccord Genuity Group Inc..
• 4/20/2026 – Smith & Nephew SNATS had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 3/29/2026 – Smith & Nephew SNATS was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Smith & Nephew SNATS Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be issued a $0.482 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a yield of 304.0%.

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.